Maxim analyst Jason McCarthy lowered the firm’s price target on Cellectar Biosciences (CLRB) to $1 from $7 and keeps a Buy rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Biotech Alert: Searches spiking for these stocks today
- Cellectar Biosciences Strategic Shift and Workforce Reduction
- Cellectar Biosciences downgraded to Perform from Outperform at Oppenheimer
- Cellectar Biosciences trading resumes
- Cellectar Biosciences reports strategic reprioritization, reduces headcount 60%